PROTACs Offer Faster Proof Of Concept, But Glues May Broaden Patient Access

Maria Soloveychik says PROTACs are often easier to design rationally because they can be built from known ligands and optimized through linker chemistry, making them useful for early clinical proof of concept. However, she notes they can be harder to develop for oral administration, while small-molecule molecular glues may offer broader patient access as simple pills. Johannes Yeh agrees that PROTACs remain valuable in early discovery because of their modular design and potential to evolve into glue-like molecules.